Comparative Pharmacology
Head-to-head clinical analysis: HIPPURAN I 131 versus NEUROLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPPURAN I 131 versus NEUROLITE.
HIPPURAN I 131 vs NEUROLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIPPURAN I 131 (iodohippurate sodium I-131) is a radiopharmaceutical that is actively transported by the renal tubules, allowing dynamic imaging of renal function. The I-131 isotope emits beta and gamma radiation, enabling scintigraphic visualization of renal perfusion and excretion.
NEUROLITE is a sodium channel blocker that stabilizes neuronal membranes and inhibits the release of excitatory neurotransmitters, thereby reducing neuronal excitability and seizure propagation.
1 mCi (37 MBq) intravenously for adults; dose adjusted based on clinical indication and imaging protocol.
300 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged in renal impairment, up to 20-40 hours in severe impairment.
Terminal half-life: 12-15 hours; steady-state reached in 2-3 days
Renal: >95% excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal: 70% unchanged; Biliary/Fecal: 15% as metabolites; 15% other
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical